US 11471442
Administration of gut-selective JAK3 inhibitor
granted A61KA61K31/416A61P
Quick answer
US patent 11471442 (Administration of gut-selective JAK3 inhibitor) held by Theravance Biopharma R&D IP, LLC expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/416, A61P, A61P1/00, A61P37/02